# Internal Review - Claude Code (Round 1)

**Role:** Journal referee (Reviewer 2, skeptical)
**Paper:** Resilient Networks: HCBS Provider Supply and the 2023 Medicaid Unwinding
**Timestamp:** 2026-02-15T16:35:00
**Pages:** 38 (30 main text + 8 appendix)

---

## PART 1: CRITICAL REVIEW

### 1. Format Check

- **Length:** 30 pages main text (before appendix), well above 25-page threshold. Appendix adds 8 pages (Data, Identification, Robustness, Heterogeneity).
- **References:** 17 references. Adequate for core citations but could be expanded (see Section 4 below).
- **Prose:** All major sections are in full paragraph form. Data section appropriately uses bullet points for variable definitions only.
- **Section depth:** Each section has 3+ substantive paragraphs. Discussion section (Section 6) is particularly strong with 5 subsections.
- **Figures:** 10 figures, all showing visible data with proper axes. **Critical issue:** Figures 1, 5, and 7 show a dramatic near-vertical drop at the end of the series (late 2024), which is almost certainly an incomplete-data artifact in the final T-MSIS release month. This visually contradicts the paper's null finding and should be addressed (trim final month or add note).
- **Tables:** 6 tables with real numbers, no placeholders. Table notes present where needed.

### 2. Statistical Methodology

a) **Standard Errors:** All coefficients have SEs in parentheses. State-clustered throughout. PASS.

b) **Significance Testing:** p-values reported for all main results. PASS.

c) **Confidence Intervals:** The 95% CI for the main TWFE coefficient is computed in text (p. 27): [âˆ’0.011, +0.063]. CIs shown graphically in event study (Figure 2) and CS-DiD (Figure 3). PASS.

d) **Sample Sizes:** N reported in all regression tables. PASS.

e) **DiD with Staggered Adoption:** The paper implements TWFE, Callaway-Sant'Anna (2021), and Sun-Abraham (2021). All three heterogeneity-robust estimators yield similar null results. PASS.

f) **Robustness:** Comprehensive battery including permutation inference (1,000 draws), leave-one-out, placebo (non-HCBS providers), placebo timing, wild cluster bootstrap, alternative outcomes (levels, asinh, per capita). PASS.

### 3. Identification Strategy

**Strengths:**
- Staggered state-level unwinding start dates (April-July 2023) provide clean treatment timing variation.
- Institutional argument for exogeneity is compelling: timing driven by administrative readiness and CMS guidance, not provider market conditions.
- 51 clusters is adequate for asymptotic cluster-robust inference.
- Multiple estimators (TWFE, CS-DiD, Sun-Abraham) all confirm the null.

**Concerns:**
- **Narrow treatment window.** Four cohorts separated by one month each (April-July 2023). By July 2023, all states are treated. The staggered design identifies the effect of *timing* (starting earlier vs. later), not the effect of unwinding vs. no unwinding. This is acknowledged in Section 6.5 (p. 29) but deserves more prominence.
- **Event study pre-trends.** The monotonic trend in Figure 2 is honestly discussed (Section 5.2, p. 15-16). The interpretation that this reflects secular HCBS growth rather than a parallel trends violation is reasonable but debatable. The paper correctly notes the event study is "uninformative" about the treatment effect.
- **Post-treatment window.** 18-21 months post-treatment is reasonable but could miss delayed exit effects. Acknowledged in limitations (p. 29).

### 4. Literature

The bibliography is adequate for core methodological and policy citations but thin by top-journal standards (17 references). Missing:

- **Medicaid managed care and provider networks:** Duggan and Hayford (2013), Currie et al. (2015) on Medicaid provider participation decisions
- **Provider supply responses to insurance shocks:** Garthwaite et al. (2012) on uncompensated care, Heim et al. (2017) on ACA marketplace effects on providers
- **HCBS-specific literature:** Harrington et al. (2011) on home health aide workforce, Newcomer et al. (2001) on HCBS waiver program evaluation
- **Null results in economics:** Andrews and Kasy (2019) on publication bias and the value of null findings

### 5. Writing Quality

a) **Prose vs. Bullets:** All major sections in paragraph form. PASS.

b) **Narrative Flow:** Excellent. The introduction hooks with the "25 million Americans" opener, builds the puzzle (hardest test case), and delivers the surprising null by the end of page 2. The paper reads as a coherent story.

c) **Sentence Quality:** Strong throughout. Active voice dominant. Good sentence rhythm variation. The discussion section (6.1) on mechanisms is the best writing in the paper.

d) **Accessibility:** Technical choices explained intuitively. Magnitudes contextualized (e.g., "for every 1,000 providers, the policy failed to push even two additional firms out of the market").

e) **Tables:** Well-structured. Table 4 now has column numbers and clear grouping. Robustness table (Table 6) has informative footnotes.

### 6. Constructive Suggestions

1. **Trim end-of-series data artifact.** Figures 1, 5, and 7 all show a dramatic drop in the final months. If this is incomplete T-MSIS reporting, trim to the last complete month. This visual "collapse" directly contradicts the resilience narrative.

2. **Power analysis.** For a null-result paper, an explicit power analysis would strengthen the contribution. What is the minimum detectable effect (MDE) given 51 states, 84 months, and the observed within-state variation? Can you rule out effects larger than, say, 5%?

3. **Billing volume per provider.** You measure the extensive margin (provider counts) but not the intensive margin (billing per provider). Even a quick analysis of mean billing per active provider would address whether providers survived but with reduced activity.

4. **Expand references.** 17 citations is light for a top-5 submission. Add 5-10 more from the health economics and provider supply literatures.

5. **Bacon decomposition.** Appendix B.2 discusses the Bacon decomposition conceptually but doesn't actually report it. Running `bacon()` from the `bacondecomp` package and reporting the weights would strengthen the claim that negative weighting is minimal.

### 7. Overall Assessment

**Key strengths:**
- Novel, policy-relevant question using first-of-its-kind T-MSIS data
- Honest, well-framed null result with comprehensive robustness
- Excellent institutional knowledge and clear writing
- Multiple heterogeneity-robust estimators all confirming the null

**Critical weaknesses:**
- End-of-series data artifact in figures is visually alarming
- Narrow treatment timing window (4 months) limits what the staggered design can identify
- No intensive margin analysis (billing per provider)
- Thin bibliography

**This is a solid, publishable paper with a genuinely important null finding.** The combination of novel data, credible identification, and honest engagement with limitations makes it competitive for AEJ: Economic Policy. The main improvements needed are cosmetic (figure trimming, expanded references) and one substantive addition (power analysis or MDE calculation).

---

DECISION: MINOR REVISION
